How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world

doi:10.5306/wjco.v13.i5.417

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3074)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

222

WORD

HTML

1419

Figures (1-1)

244

Tables (1-1)

235

Sum=2215

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

308

Download

551

Sum=859

May 24, 2022 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Clin Oncol. May 24, 2022; 13(5): 417-422
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.417

Open in New Tab Full Size Figure Download Figure

Figure 1 Kaplan-Meier overall survival and progression free survival curves according to clinical variables. A: Overall survival (OS) Kaplan-Meier curve according to nal-IRI treatment duration; B: Progression free survival (PFS) Kaplan-Meier curve according to nal-IRI treatment duration; C: OS Kaplan-Meier curve according to baseline haemoglobin levels; D: PFS Kaplan-Meier curve according to baseline haemoglobin levels; E: OS Kaplan-Meier curve according to occurrence of grade > 2 anaemia; F: OS Kaplan-Meier curve according to occurrence of grade > 2 anaemia; G: OS Kaplan-Meier curve according to the need for erythropoietin administration; H: PFS Kaplan-Meier curve according to the need for erythropoietin administration.

Citation: Pretta A, Spanu D, Mariani S, Liscia N, Ziranu P, Pusceddu V, Puzzoni M, Massa E, Scartozzi M, Lai E. How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world. World J Clin Oncol 2022; 13(5): 417-422
URL: https://www.wjgnet.com/2218-4333/full/v13/i5/417.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i5.417